Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) EBITDA Margin (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed EBITDA Margin for 2 consecutive years, with 1082.08% as the latest value for Q2 2023.

  • Quarterly EBITDA Margin rose 1885297.0% to 1082.08% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 4682.74% through Mar 2024, down 83815.0% year-over-year, with the annual reading at 2862.25% for FY2022, 1163836.0% up from the prior year.
  • EBITDA Margin hit 1082.08% in Q2 2023 for Pasithea Therapeutics, down from 5935.29% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 5935.29% in Q1 2023 to a low of 19935.05% in Q2 2022.